A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

This study tests a three-drug combination — adagrasib (a KRAS G12C inhibitor), cetuximab (a targeted antibody), and cemiplimab (an immunotherapy) — in patients with advanced colorectal cancer that has a specific KRAS G12C gene mutation. KRAS G12C mutations are found in roughly 3–4% of colorectal cancers and are difficult to treat. **You may be eligible if...** - You are 18 or older with metastatic or unresectable colorectal cancer - Your tumor has a confirmed KRAS G12C mutation - Your cancer is microsatellite stable - You have received at least one prior line of chemotherapy for metastatic disease - You have measurable disease and are willing to undergo tumor biopsies **You may NOT be eligible if...** - Your tumor does not have a KRAS G12C mutation - You have not yet tried chemotherapy for metastatic disease - You are unwilling to undergo mandatory tumor biopsies Talk to your doctor to see if this trial is right for you.